## **Expression of concern**

## ATP11B mediates platinum resistance in ovarian cancer

Myrthala Moreno-Smith, J.B. Halder, Paul S. Meltzer, Tamas A. Gonda, Lingegowda S. Mangala, Rajesha Rupaimoole, Chunhua Lu, Archana S. Nagaraja, Kshipra M. Gharpure, Yu Kang, Cristian Rodriguez-Aguayo, Pablo E. Vivas-Mejia, Behrouz Zand, Rosemarie Schmandt, Hua Wang, Robert R. Langley, Nicholas B. Jennings, Cristina Ivan, Jeremy E. Coffin, Guillermo N. Armaiz, Justin Bottsford-Miller, Sang Bae Kim, Margaret S. Halleck, Mary J.C. Hendrix, William Bornman, Menashe Bar-Eli, Ju-Seog Lee, Zahid H. Siddik, Gabriel Lopez-Berestein, and Anil K. Sood

Original citation: J Clin Invest. 2013;123(5):2119-2130. https://doi.org/10.1172/JCI65425.

Citation for this expression of concern: J Clin Invest. 2018;128(7):3199. https://doi.org/10.1172/JCI122301.

The Editors recently became aware that Figure 3B appears to use a set of images that were previously published in a 2009 *Clinical Cancer Research* paper with different sample labels (doi: 10.1158/1078-0432.CCR-08-2306). Additionally, the empty liposome and control siRNA PCNA-stained panels appear to be the same. The Editorial Board is pursuing further investigation of this matter, and we will inform our readers of the outcome when the investigation is complete.